Cardiovascular Parameters Correlated with Metabolic Syndrome in a Rural Community Cohort of Korea: The ARIRANG Study by Ahn, Min-Soo et al.
© 2010 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934
eISSN 1598-6357
Cardiovascular Parameters Correlated with Metabolic Syndrome 
in a Rural Community Cohort of Korea: The ARIRANG Study
Although metabolic syndrome (MetS) is associated with increased cardiovascular mortality 
and the development of atherosclerosis, consensus is still lacking on the status of 
cardiovascular function and geometry in MetS patients. We investigated the relation 
between MetS and left ventricle (LV) geometry and function, carotid intima-media 
thickness (IMT) and arterial stiffness in a community-based cohort of 702 adult subjects. 
Subjects were categorized into three groups according to the number of MetS components 
present, as defined by the Adult Treatment Panel Ш guidelines: 1) Absent (0 criteria), 2) 
Pre-MetS (1-2 criteria) or 3) MetS (≥3 criteria). In female subjects, LV mass, LV mass/
height
2.7, deceleration time, and aortic pulse wave velocity increased, and E/A ration 
decreased in a stepwise manner across the three groups. These changes were not observed 
in male subjects. The mean carotid IMT was higher in the MetS group than in the other two 
groups. The degree of MetS clustering is found to be strongly correlated with geometric 
eccentricity of LV hypertrophy, diastolic dysfunction and arterial changes irrespective of 
age and blood pressure status, particularly in females. Waist circumference is found to have 
the most powerful effect on cardiovascular parameters.
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INTRODUCTION
Metabolic syndrome (MetS) has an age-adjusted prevalence rate 
of 24% in adults in the USA and 11-19% in Korea (1-4). It is char-
acterized by a cluster of clinical features that include abdominal 
obesity, insulin resistance, hyperglycemia, hypertension, and 
dyslipidemia. These risk factors act synergistically to increase 
the risk of adverse cardiovascular events including coronary ar-
tery disease and congestive heart failure, and are associated with 
high cardiovascular morbidity and mortality (5, 6). The progres-
sive addition of MetS risk factors such as obesity, diabetes, and/
or dyslipidemia is associated with increased left ventricular (LV) 
mass, an effect which is independent of hypertension. The ef-
fects of MetS on cardiovascular structure and function are not 
well characterized (7). We therefore investigated the relation 
between MetS and LV geometry and function, carotid intima-
media thickness (IMT), and arterial stiffness using a sample 
from the Korean general population. 
MATERIALS AND METHODS
Study population 
The ARIRANG study (Atherosclerosis RIsk of a Rural Area kore-
aN General population) is an ongoing study of cardiovascular 
and metabolic risk factors that is being conducted in the rural 
area of Wonju, Gangwon-do, Korea. The ARIRANG study was 
approved by the Ethics Committee of the Wonju Christian Hos-
pital, Wonju College of Medicine, Yonsei University (Wonju, 
Gangwon-do, Korea, Approval number: CR105024), and writ-
ten informed consent was obtained from all study participants. 
In the present study, we investigated a total of 702 adults from 
the ARIRANG cohort who had all previously undergone com-
plete echocardiography assessment and measurement of IMT 
and pulse wave velocity (PWV). For the present study, all par-
ticipants underwent a complete cardiovascular evaluation fol-
lowing 8 hr of fasting, which included: 1) history, physical exam-
ination, and anthropometric analysis; 2) measurement of heart 
rate and blood pressure (BP, measured after 10 min resting in a 
sitting position, was expressed as the average of three consecu-Ahn M-S, et al.  •  Cardiovascular Changes in the Metabolic Syndrome 
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tive measurements taken from each arm); 3) measurement of 
fasting blood glucose and insulin levels (in subjects not receiv-
ing insulin and/or oral hypoglycemic agents); and 4) measure-
ment of fasting plasma lipids (i.e., concentrations of triglyceride, 
high-density lipoprotein cholesterol [HDL-C], total cholesterol, 
and low-density lipoprotein cholesterol [LDL-C]). A diagnosis 
of MetS was assigned according to the amended National Cho-
lesterol Education Program’s Adult Treatment Panel III (ATP-III) 
Guidelines and using the South Asian-specific value for waist 
circumference. MetS was diagnosed in individuals meeting three 
or more of the following criteria: (a) increased waist circumfer-
ence (≥90 cm in males or ≥80 cm in females); (b) increased fast-
ing triglyceride level (≥150 mg/dL); (c) high BP (≥130/≥85 mmHg) 
or receiving antihypertensive therapy; (d) decreased HDL-C lev-
el (<40 mg/dL in males or <50 mg/dL in females) or receiving 
specific treatment for this lipid abnormality; and (e) impaired 
fasting glucose level (≥110 mg/dL) (1, 4).
Echocardiography
Echocardiography was performed using the harmonic imaging 
mode by use of a 3-MHz transducer and commercial ultrasound 
system (Vivid-7; General Electric–Vingmed, Milwaukee, WI, 
USA). LV internal dimensions, LV wall thickness, and LV ejec-
tion fraction (LVEF, by modified Simpson’s rule) were measured 
according to published recommendations (8). LV mass was cal-
culated as recommended by the American Society of Echocar-
diography using the equation: LV mass =1.04×([PW+VS+LVDd]
3
×[LVDd]
3)×0.8+0.6, where PW is the M-mode posterior wall thick-
ness of the LV, VS is the M-mode interventricular septal thick-
ness, and LVDd is the M-mode LV dimension with the short axis 
view at end-diastole (9). Allometric height-based adjustments 
were used since height
2.7 has been reported to offer the most 
accurate estimation of LV hypertrophy and risk factors for path-
ological changes in heart structure, particularly in obese sub-
jects (10). Relative wall thickness (RWT), which increases with 
concentric remodeling and concentric hypertrophy, was calcu-
lated as 2×PW/LVDd. The left atrial (LA) dimension was mea-
sured by 2D-guided M-mode echocardiography using the para-
sternal short-axis view at the base of the heart, as recommend-
ed by the American Society of Echocardiography (11). Three LA 
dimensions were used to calculate the LA volume as an ellipse 
using the formula: LA volume=π/6 (SA1 • SA2 • LA), where SA1= 
the M-mode LA dimension, and SA2 and LA are measurements 
of the short- and long-axis with the apical four-chamber view at 
ventricular end-systole, respectively (12). The LA volume index 
was calculated by dividing the LA volume by the body surface 
area (BSA, m
2). 
  Transmitral inflow velocities were measured using Pulsed-
Wave Doppler (PWD) and the apical 4-chamber view, with the 
sample volume placed at the mitral valve leaflet tips (13). Mea-
surements of the transmitral early diastolic (E-wave) and atrial 
(A-wave) velocities were taken in order to calculate the E/A ra-
tio and E-wave deceleration time (13). Tissue Doppler imaging 
(TDI) and the apical 4-chamber view were used to measure the 
LV myocardial velocities, with the sample volume placed at the 
septal mitral annulus (13, 14). Measurements included the ear-
ly diastolic velocity (E’) and late diastolic velocity (A’). The E/E’ 
ratio was then calculated (15). 
Measurement of carotid IMT and PWV
Measurement was performed using a validated procedure, as 
described previously (16). An ultrasound system (Vivid-7; Gen-
eral Electric–Vingmed) and a phased array 12-MHz transducer 
were used to obtain a high-resolution B-mode ultrasound view 
of the far wall of the common carotid artery. The common ca-
rotid arteries were explored, starting from a position 1 cm be-
low the flow divider and between the internal and external ca-
rotid arteries. Measurements were taken by tracing the leading 
edge of the lumen-intima and the media-adventitia interfaces 
in plaque-free areas. 
  PWVs were measured using an automatic waveform analyzer 
(PP-1000, Hanbyul Meditech, Jeonju, Korea). This provides re-
gional PWV values using simultaneous electrocardiographic, 
phonographic, and pulse wave measurements from four differ-
ent arterial sites (carotid, femoral, radial, and dorsalis pedis). 
The PWV was then calculated from the pulse transit time and 
the distance travelled by the pulse between the two recording 
sites: PWV=Distance (meters)/Transit time (seconds). Surface 
distances for the measurement of the PWV were calculated from 
the subject’s height and from anthropomorphic data from the 
Korean population. Three different PWV values were calculat-
ed: aortic, heart-to-radial, and femoral-to-ankle. The aortic PWV 
represents the velocity between the carotid artery and the fem-
oral artery. The heart-to-radial PWV (hrPWV) and the femoral-
to-ankle PWV (faPWV) were calculated on the basis of the ca-
rotid-radial and the femoral-dorsalis pedis transit times, respec-
tively. 
Statistical analysis
Statistical analyses were performed using SPSS 11.0.1 software 
(SPSS Inc., Chicago, IL, USA). Males and females were analyzed 
separately since sex is known to have an important effect. The 
study cohort was divided into three groups according to the num-
ber of MetS criteria present: Absent (0 criteria), Pre-MetS (1–2 
criteria), and MetS (≥3 criteria). The data are presented as mean 
±standard deviation in the case of continuous variables and as 
proportions in the case of categorical variables. Chi-square sta-
tistical analysis was used to determine differences in categorical 
variables between the three groups. Analysis of variance (ANO-
VA) was used to determine differences in continuous variables 
between the three groups. P values for the comparison of echo-
cardiographic parameters of cardiac geometry and function Ahn M-S, et al.  •  Cardiovascular Changes in the Metabolic Syndrome 
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across the three groups were based on analysis of covariance 
(ANCOVA), adjusted for age and BP. The comparisons of IMT 
and PWV were analyzed by ANCOVA, and adjusted for age, BP, 
and smoking habits. Given the co-linearity of the components 
of the metabolic syndrome, the effect sizes of the components 
of the metabolic syndrome on cardiac geometry, IMT and PWV 
adjusted for age and compared using single linear regression 
analysis. A two-sided P<0.05 was considered statistically signifi-
cant.
RESULTS
Characteristics of the study population
The prevalence of MetS was 38.6% (36.6% of males and 40.0% 
of females, P=0.20). The demographic and clinical characteris-
tics of the 702 subjects (mean age, 55.5±8.5 yr; 41% male) are 
reported separately for each sex, according to the number of 
MetS criteria present (Tables 1, 2). Due to the sampling effect, the 
values of the MetS components (waist circumference, BP, fasting 
glucose, triglyceride level), weight, and hip circumference mea-
surements were found to increase across the three groups, while 
the HDL-cholesterol levels decreased across the three groups. 
In female subjects, a stepwise increase in the level of total cho-
lesterol and LDL cholesterol, and in the prevalence of cardio-
vascular disease (cerebrovascular accident, myocardial infarc-
tion and hypertension), was observed across the three groups. 
No significant differences in these factors were observed in male 
Table 1. Demographic and clinical characteristics of male subjects
Parameters
Absent
(n=27)
Pre-MetS 
(n=155)
Mets
(n=105)
P 
value
Age (yr)   58.4±9.5 57.4±8.1   55.3±8.5 0.08
Smoking (%) 13 (48.1) 60 (39.2) 44 (41.9) 0.67
History of CVA (%) 0 (0.0) 4 (3.1) 7 (8.0) 0.15
History of MI 0 (0.0) 4 (3.1) 4 (4.6) 0.59
History of hypertension 0 (0.0) 37 (27.4) 25 (27.5) 0.27
History of hyperlipidemia 0 (0.0) 7 (5.5) 7 (8.0) 0.41
DM (%) 0 (0.0) 15 (11.5)   3 (16.5) 0.13
Height (cm) 164.6±5.1 166.1±5.4 167.0±5.3 0.10
Weight (kg)   59.4±8.2   66.2±9.1   73.7±9.5 0.00
Waist (cm)   80.8±5.6   85.8±7.2   92.4±7.3 0.00
Hip (cm)   93.3±4.3   96.2±5.4 100.8±5.9 0.00
Systolic BP (mmHg) 112.8±8.8   131.5±18.1   138.8±20.8 0.00
Diastolic BP (mmHg)   73.5±6.8     82.6±10.2     85.8±14.2 0.00
Glucose (mg/dL)   87.8±9.9     96.0±19.7   106.3±32.1 0.00
Total cholesterol (mg/dL)   194.7±39.3   199.3±38.2   201.3±37.5 0.72
HDL-cholesterol (mg/dL)   52.9±8.7     47.5±11.1   38.8±8.0 0.00
LDL-cholesterol (mg/dL)    109.5±36.2   111.3±32.9   113.8±34.2 0.77
Triglyceride (mg/dL)     97.4±25.6  158.5±101.0     238.8±142.6 0.00
CRP (mg/dL)     2.02±3.78 1.89±3.13     3.27±7.34 0.10
Data are expressed as mean±standard deviation (SD) or frequency (%). Chi-square 
test was used for smoking status and past history; ANOVA was used for all other 
variables.
MetS, Metabolic syndrome; CVA, cerebrovascular accident; MI, myocardial infarction; 
DM, diabetes mellitus; BP, blood pressure; LDL, low-density lipoprotein; HDL, high-
density lipoprotein; CRP, C-reactive protein.  
Table 2. Demographic and clinical characteristics of female subjects
Parameters
Absent
(n=41)
Pre-MetS 
(n=208)
Mets
(n=166)
P 
value
Age (yr)   49.3±7.2    53.0±8.1 57.9±7.8 0.00
Smoking (%) 2 (4.9)    3 (1.5)   2 (1.2) 0.26
History of CVA (%) 0 (0.0)    0 (0.0)   4 (3.5) 0.02
History of MI 0 (0.0)    4 (2.3)   8 (7.2) 0.046
History of hypertension 0 (0.0)   30 (16.6)   56 (40.9) 0.00
History of hyperlipidemia 0 (0.0) 14 (8.0) 10 (8.8) 0.46
DM (%) 0 (0.0)    5 (2.9 )   23 (19.2) 0.00
Height (cm) 155.8±4.8 153.7±5.6    153.2±5.5 0.03
Weight (kg)   53.9±6,1   57.2±8.6      61.8±8.2 0.00
Waist (cm)   72.4±4.6   80.3±8.7      87.5±7.4 0.00
Hip (cm)   92.3±4.1   94.9±6.9      98.9±6.4 0.00
Systolic BP (mmHg) 113.2±8.8   122.3±16.3    136.9±16.0 0.00
Diastolic BP (mmHg)   72.1±7.0     77.2±11.0      84.7±10.7 0.00
Glucose (mg/dL)   87.5±7.4   87.7±7.4    100.0±27.6 0.00
Total cholesterol (mg/dL)   198.4±35.5   200.9±37.6    213.8±41.5 0.003
HDL-cholesterol (mg/dL)   56.7±5.8     48.4±10.8      42.3±7.9 0.00
LDL-cholesterol (mg/dL)    108.2±30.2   117.9±29.6    125.4±35.6 0.004
Triglyceride (mg/dL)     79.8±23.8   107.0±56.9    198.7±128.8  0.00
CRP (mg/dL)     0.98±1.89     1.68±3.26 1.80±2.22 0.23
Data are expressed as mean±standard deviation (SD) or frequency (%). Chi-square 
test was used for smoking status and past history; ANOVA was used for all other 
variables. 
MetS, Metabolic syndrome; CVA, cerebrovascular accident; MI, myocardial infarction; 
DM, diabetes mellitus; BP, blood pressure; LDL, low-density lipoprotein; HDL, high-
density lipoprotein; CRP, C-reactive protein. 
Table 3. Echocardiographic characteristics of male subjects 
Echocardiographic
   parameters
Absent
(n=27)
Pre-MetS 
(n=155)
Mets
(n=105)
P 
value
LA volume (mL) 29.2±8.7   34.4±11.0   38.0±11.7 0.001
LA volume/BSA (mL/m
2) 17.7±5.0 19.6±5.9 20.6±6.1 0.04
LVDd (cm)   5.09±0.55   5.26±0.58   5.37±0.61 0.20
LVDs (cm)   3.39±0.57   3.50±0.52   0.59±0.61 0.42
LV EF (%) 61.9±7.4 61.3±7.5 61.1±8.1 0.96
IVSd (cm)   0.68±0.13   0.72±0.17   0.73±0.19 0.93
LVPWd (cm)   0.74±0.15   0.78±0.15   0.78±0.18 0.36
LV mass (g) 121.8±30.9 137.9±35.9 146.1±43.8 0.07
LV mass/BSA (g/m
2)   73.9±16.7   79.0±19.1   79.2±23.4 0.73
LV mass/height
2.7 (g/m
2.7) 31.8±8.3 35.0±8.8   36.8±11.7 0.09
Relative wall thickness    0.30±0.07   0.30±0.08   0.30±0.09 0.83
E (m/sec)   0.67±0.16   0.65±0.16   0.66±0.18 0.87
Deceleration time (msec) 240.8±49.6 233.8±81.5 235.9±58.0 0.75
A (m/sec)   0.71±0.15   0.70±0.14   0.73±0.17 0.35
E/A   0.97±0.27   0.96±0.34   0.95±0.31 0.82
E’ (cm/sec)   0.08±0.01   0.08±0.02   0.07±0.02 0.25
A’ (cm/sec)   0.11±0.02   0.10±0.02   0.10±0.02 0.22
E/E’   7.68±1.56   8.81±2.56   9.27±2.97 0.09
Data are expressed as mean±standard deviation (SD). 
All variables were analyzed using ANCOVA, adjusted for age, and systolic and diastolic 
blood pressure. 
MetS, Metabolic syndrome; LA, left atrium; BSA, body surface area; LV, left ventricle; 
LVDd, end-diastolic left ventricular dimension; LVDs, end-systolic left ventricular dimen–
sion; LV EF, left ventricular ejection fraction; IVSd, end-diastolic interventricular septal 
thickness; LVPWd, end-diastolic left ventricular posterior wall thickness; E, peak mitral 
flow velocity of the early rapid filling wave; A, peak mitral flow velocity of the late filling 
wave; E’, early diastolic velocity of the mitral annulus; A’, late diastolic velocity of the 
mitral annulus. 1048   http://jkms.org
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subjects. 
Cardiac geometry and function
The mean LVEF was 62.7±7.6% and the mean LV mass was 124.5 
±38.9 g. LVEF was lower in males (61.3±7.7% vs. 63.7±7.4%, P< 
0.001). LV mass and LV mass/BSA were significantly higher in 
males (139.4±39.1 g vs. 114.1±35.3 g, 78.6±20.6 g/m
2 vs. 72.0± 
20.3 g/m
2, P<0.001). No sex difference was observed for LV mass/ 
height
2.7 (35.4±10.0 g/m
2.7 vs. 36.0±11.6 g/m
2.7, P=0.49). E/E’ was 
significantly lower in males (8.9±2.7 vs. 10.9±3.2, P<0.001). The 
LA volume index was similar in both sexes. In males, the LA vol-
ume and LA volume index showed a stepwise increase across 
the three groups, but no inter-group differences were observed 
for the other echocardiographic parameters (Table 3). In females, 
LV mass, LV mass/height
2.7, and LA volume increased in a step-
wise manner across the three groups; no inter-group differenc-
es were observed for LVEF. LVDd and RWT showed a tendency 
Table 4. Echocardiographic characteristics of female subjects
Echocardiographic
parameters
Absent
(n=41)
Pre-MetS
(n=208)
Mets
(n=166)
P 
value
LA volume (mL) 28.6±6.7 30.4±7.8   34.5±10.2 0.003
LA volume/BSA (mL/m
2) 18.7±4.2 19.5±4.6 21.3±6.0 0.18
LVDd (cm) 4.89±0.35   4.93±0.54   5.07±0.56 0.14
LVDs (cm)   3.22±0.29   3.21±0.47   3.28±0.50 0.27
LV EF (%) 62.5±6.2 63.7±7.1 63.8±8.0 0.74
IVSd 0.59±0.13   0.65±0.14   0.70±0.17 0.06
LVPWd 0.66±0.14   0.70±0.15   0.75±0.16 0.25
LV mass (g) 97.2±26.0 108.8±33.0 127.9±37.0 0.01
LV mass/BSA (g/m
2) 63.9±17.1   69.6±19.2   77.1±21.4 0.32
LV mass/height
2.7 (g/m
2.7) 29.5±8.1   34.3±10.7   39.7±12.2 0.01
Relative wall thickness  0.27±0.07   0.29±0.07   0.30±0.08 0.67
E (m/sec) 0.82±0.13   0.76±0.17   0.71±0.16 0.33
Deceleration time (msec) 202.8±47.2 218.9±51.5 240.5±56.4 0.02
A (m/sec) 0.68±0.15   0.76±0.18   0.83±0.18 0.35
E/A 1.25±0.32   1.05±0.33   0.88±0.24 0.01
E’ (cm/sec) 0.10±0.02   0.08±0.02   0.06±0.02 0.00
A’ (cm/sec) 0.09±0.02   0.10±0.02   0.10±0.02 0.66
E/E’ 8.8±2.2 10.6±2.8 11.7±3.5 0.26
Data are expressed as mean±standard deviation (SD). 
All variables were analyzed using ANCOVA, adjusted for age, and systolic and diastolic 
blood pressure.
MetS, Metabolic syndrome; LA, left atrium; BSA, body surface area; LV, left ventricle; 
LVDd, end-diastolic left ventricular dimension; LVDs, end-systolic left ventricular dimen–
sion; LV EF, left ventricular ejection fraction; IVSd, end-diastolic interventricular septal 
thickness; LVPWd, end-diastolic left ventricular posterior wall thickness; E, peak mitral 
flow velocity of the early rapid filling wave; A, peak mitral flow velocity of the late filling 
wave; E’, early diastolic velocity of the mitral annulus; A’, late diastolic velocity of the 
mitral annulus. 
Table 5. Effect size of components of the metabolic syndrome on left ventricular 
mass in females (LV mass/height 
2.7)
Parameters B R
2  P
Waist circumference (cm) 0.471 0.291 0.000
Systolic blood pressure (mmHg) 0.063 0.173 0.045
Diastolic blood pressure (mmHg) 0.067 0.169 0.148
HDL-cholesterol (mg/dL) 0.033 0.165 0.514
Triglyceride (mg/dL) 0.003 0.165 0.617
Fasting glucose (mg/dL) 0.038 0.169 0.164
All variables were analyzed using single linear regression analysis, adjusted for age.
B, non-standardized regression coefficient; LV, left ventricle; HDL, high-density lipo–
protein.
Table 6. Effect size of components of the metabolic syndrome on deceleration time 
in females 
Parameters B R
2 P
Waist circumference (cm) 1.528 0.101 0.000
Systolic blood pressure (mmHg) 0.409 0.060 0.009
Diastolic blood pressure (mmHg) 0.698 0.065 0.003
HDL-cholesterol (mg/dL) 0.200 0.045 0.439
Triglyceride (mg/dL) 0.056 0.055 0.033
Fasting glucose (mg/dL) 0.353 0.060 0.009
All variables were analyzed using single linear regression analysis, adjusted for age. 
B, non-standardized regression coefficient; LV, left ventricle; HDL, high-density lipo–
protein. 
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to increase across the three groups, but these differences did not 
achieve statistical significance. The E’ showed a stepwise de-
crease across the three groups, and deceleration time increased 
across the three groups. Since the A wave velocity showed a ten-
dency to increase and the E wave velocity showed a tendency 
to decrease, the E/A ratio decreased in a stepwise manner across 
the three groups (Table 4). In comparing the effect size of each 
component of the metabolic syndrome, waist circumference 
was found to have the most powerful effect on both LV mass/
height
2.7 and deceleration time in female subjects (Tables 5, 6).
Carotid IMT and PWV
IMT ranged from 0.22 to 1.75 mm, with a mean of 0.62 mm and 
a standard deviation (S.D.) of 0.15 mm, and was similar in both 
sexes. The coefficient of variation of IMT was 24.1%. A signifi-
cant positive correlation was observed between IMT and sys-
tolic blood pressure (r=0.098, P=0.01) and age (r=0.236, P=0.00), 
irrespective of smoking status. IMT was also found to be signifi-
cantly correlated with hrPWV (r=0.098, P=0.03) and faPWV (r= 
0.093, P=0.04), but not with aortic PWV. The mean aortic PWV 
was 7.66±1.26 m/sec (coefficient of variation=16.4%), hrPWV 
was 8.12±1.07 m/sec (coefficient of variation=13.0%), and faPWV 
was 10.15±1.35 m/sec (coefficient of variation=13.3%). PWV was 
significantly higher in males (Aortic PWV, 8.05±1.25 m/sec vs. 
7.38±1.2 m/sec; hrPWV, 8.61±1.03 m/sec vs. 7.77±0.95 m/sec; 
faPWV, 10.34±1.30 m/sec vs. 10.01±1.36 m/sec, P<0.01). Aortic 
PWV and faPWV were significantly correlated with systolic and 
diastolic blood pressure and age; hrPWV was correlated with BP, 
but not with age. Significant differences were observed for all 
regional PWVs in relation to smoking status (non-smoker, ex-
smoker, current smoker).
  In males, IMT was significantly higher in the MetS group com-
pared with the pre-MetS group (P=0.01). All regional PWVs were 
similar across the three groups (Figs. 1, 2). 
  In females, IMT was significantly higher in MetS group com-
pared with the two other groups (Fig. 1). Aortic PWV increased 
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in a stepwise manner across the three groups (6.97±0.97 m/sec, 
7.16±1.13 m/sec, 7.74±1.26 m/sec, P=0.049) (Fig. 3). hrPWV and 
faPWV showed a tendency to increase in a stepwise manner 
across the three groups, but these differences did not achieve 
statistical significance (Fig. 3). In comparing the effect size of 
each component of the metabolic syndrome, waist circumfer-
ence was found to have the largest effect on IMT (Table 7).
DISCUSSION
The present study evaluated echocardiographic measurements 
of LV geometry and function, IMT and PWV assessment of arte-
rial stiffness in a cross sectional cohort of subjects grouped ac-
cording to the number of MetS criteria present. This study clear-
ly demonstrated a sex specific relationship between MetS and 
cardiovascular function and geometry. The fact that the ANCO-
VA model was used reduces the likelihood that this finding was 
an artifact of covariance (age, BP, or smoking). In females, we 
found that: 1) LVEF, which reflects LV systolic function, was with-
in normal limits in all three groups, 2) RWT results were similar 
in all three groups, while LV mass and LV mass/height
2.7 increas–
ed progressively across the three groups, 3) E/A and deceleration 
time, which reflects LV diastolic function, showed progressive 
impairment across the three groups after adjustment for age and 
BP, and 4) aortic PWV increased progressively across the three 
groups after adjustment for age, BP and smoking status. In males, 
no differences were found across the three groups, except in LA 
volume index and IMT. The results of this study suggest that an 
increase in the number of MetS criteria is associated, in an in-
dependent manner, with subclinical eccentric LV hypertrophy, 
diastolic dysfunction, and increased arterial stiffness, irrespective 
of age and BP. The effects of MetS were found to be pronounced 
in females, but not in males. These findings did not change when 
subjects with diabetes and hypertension were excluded (data 
not shown). When LV mass was indexed for body surface area 
(a normalization that minimizes the effect of obesity since body 
weight is included in its computation), metabolic risk factors 
showed no significant effects. This finding strongly confirms that 
obesity, when present, is the feature that tracks the cumulative 
effect of the other risk factors (hypercholesterolemia and dia-
Table 7. Effect size of components of the metabolic syndrome on IMT
Parameters
Females Males
B R
2 P B R
2 P
Waist circumference (cm) 0.003 0.080  0.003  0.003 0.071   0.001
Systolic blood pressure (mmHg) 0.000 0.069 0.355    0.000 0.036   0.593
Diastolic blood pressure (mmHg) 0.001 0.070 0.218 -0.001 0.039   0.312
HDL-cholesterol (mg/dL) 0.000 0.067 0.588 -0.001 0.046   0.074
Triglyceride (mg/dL) 0.000 0.067 0.571  0.000 0.068   0.002
Fasting glucose (mg/dL) 0.000 0.067 0.891  0.000 0.068   0.002
All variables were analyzed using single linear regression analysis, adjusted for age. 
B, non-standardized regression coefficient; LV, left ventricle; HDL, high-density lipoprotein. 
betes).
  Although several recent studies have reported impaired LV di-
astolic function in MetS patients, consensus is still lacking on the 
effect of MetS on cardiac function and geometry. In the Strong 
Heart Study, MetS was found to be associated with reduced LV 
systolic and diastolic function and LV dimensions, while LV mass 
and RWT were found to be higher in the MetS group (17). In con-
trast, Grandi et al. (18) found that only LV diastolic function was 
reduced in MetS, and that LV systolic function was normal in 
clinically hypertensive non-diabetic subjects. They also report-
ed that both LV mass and relative wall thickness were signifi-
cantly increased in the MetS group, but that LV dimensions were 
similar in both groups. Mule et al. (19) reported that MetS has a 
deleterious effect on hypertension-related target organ damage. 
They observed increased LV mass, RWT, and deceleration times 
in hypertensive subjects with MetS compared with a hyperten-
sive cohort without MetS. In a population-based study, Sun–
dst–rom et al. (20) demonstrated a strong correlation between 
MetS and left ventricular mass and relative wall thickness, a cor-
relation which was independent of blood pressure status. Only 
a few previous studies of the impact of MetS on LV mass have 
conducted separate analyses for males and females, and these 
studies have reported conflicting findings. Schillaci et al. (21) 
found that MetS had a more pronounced effect on LV hypertro-
phy and function in females. Our results support the hypothesis 
that MetS is associated with LV diastolic dysfunction in females 
only, even in subjects without LV systolic dysfunction, and irre-
spective of BP status. However, in the present study, changes in 
LV geometry tended toward eccentric hypertrophy, and waist 
circumference was found to have the most significant effect on 
left ventricular functional and geometric change. 
  In the present study, MetS was associated with increased ca-
rotid IMT and aortic PWV, and this effect was independent of 
age, BP, and smoking status, particularly in females. In females, 
hrPWV and faPWV showed a tendency to increase in a stepwise 
manner across the three groups, but these differences did not 
achieve statistical significance. This suggests that the cluster of 
MetS components may interact synergistically to increase arte-
rial stiffness, particularly in females. Several previous studies 
have reported that the grouping of insulin resistance syndrome Ahn M-S, et al.  •  Cardiovascular Changes in the Metabolic Syndrome 
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components is associated with excessive carotid IMT, beyond a 
level attributable to an additive effect, and that MetS was inde-
pendently associated with carotid IMT and arterial stiffness (22, 
23). However, most of the studies that have investigated associ-
ations with MetS and its components have focused on one spe-
cific arterial segment, such as the aorta, brachial-ankle segment, 
or the lower limb, or alternatively, one arterial site such as the 
brachial and (more frequently) the carotid artery, and their re-
sults have been conflicting. There have been few studies of sex-
specific MetS effects on arterial stiffness. Schillaci et al. (24) dem-
onstrated that MetS was independently associated with higher 
aortic velocity, but not with higher upper limb pulse wave ve-
locity. Ferreira et al. (25) reported that stiffness in the femoral 
arteries was higher than that in the carotid arteries. Other stud-
ies have evaluated central and peripheral arterial segments and 
reported that MetS is associated with increased central and peri–
pheral arterial stiffness in females (26). The present study show–
ed an association between MetS and aortic PWV in females, but 
these findings did not reach statistical significance. Further stud-
ies are required to demonstrate the relative impact of MetS on 
PWV in differing arterial regions. 
  The mechanism underlying the influence of sex on the asso-
ciation between MetS and LV geometry and function, arterial 
stiffness, and structural change remains unknown. It will be nec-
essary to conduct further studies in order to elucidate the nature 
of this sex-specific effect. 
  The present study has important limitations. Its cross-section-
al design precludes the performance of outcome analyses. The 
sample size was relatively small, especially for the group with 
no MetS components. Ambulatory BP measurements, which 
have been shown to be more predictive of hypertensive end-or-
gan damage, were not performed. Although PWV may vary ac-
cording to the time of day, these variables were consistently mea-
sured in the morning.
  In conclusion, clustering of MetS components is indepen-
dently associated with subclinical eccentric LV hypertrophy, di-
astolic dysfunction, and increased aortic wall stiffness, particu-
larly in females, irrespective of age and BP status. Waist circum-
ference has the most powerful influence on LV geometry and 
function and IMT. 
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